key: cord-0997955-5s01gqrx
authors: Ong, Sean Wei Xiang; Chiew, Calvin J; Ang, Li Wei; Mak, Tze-Minn; Cui, Lin; Toh, Matthias Paul H S; Lim, Yi Ding; Lee, Pei Hua; Lee, Tau Hong; Chia, Po Ying; Maurer-Stroh, Sebastian; Lin, Raymond T P; Leo, Yee-Sin; Lee, Vernon J; Lye, David Chien; Young, Barnaby Edward
title: Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta)
date: 2021-08-23
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab721
sha: ea6e93c8e163d7b0dbb2bd1bdd2421c4b7e01166
doc_id: 997955
cord_uid: 5s01gqrx

BACKGROUND: he impact of SARS-CoV-2 variants of concern (VOCs) on disease severity is unclear. In this retrospective study, we compared outcomes of patients infected with B.1.1.7, B.1.351, and B.1.617.2 with those with wild-type strains from early 2020. METHODS: National surveillance data from 1-January-2021 to 22-May-2021 were obtained from the Ministry of Health, and outcomes in relation to VOC were explored. Detailed patient level data from all patients with VOC infection admitted to our center between 20-December-2020 and 12-May-2021 were analyzed. Clinical outcomes were compared with a cohort of 846 patients admitted from January-April 2020. RESULTS: 829 patients in Singapore in the study period were infected with these 3 VOCs. After adjusting for age and sex, B.1.617.2 was associated with higher odds of oxygen requirement, ICU admission, or death (adjusted odds ratio (aOR) 4.90, [95% CI 1.43-30.78]). 157 of these patients were admitted to our center. After adjusting for age, sex, comorbidities, and vaccination, aOR for pneumonia with B.1.617.2 was 1.88 [95% CI 0.95-3.76]) compared with wild-type. These differences were not seen with B.1.1.7 and B.1.351. Vaccination status was associated with decreased severity. B.1.617.2 was associated with significantly lower PCR Ct values and longer duration of Ct value ≤30 (median duration 18 days for B.1.617.2, 13 days for wild-type). CONCLUSIONS: There was a signal toward increased severity associated with B.1.617.2. The association of B.1.617.2 with lower Ct value and longer viral shedding provides a potential mechanism for increased transmissibility. These findings provide an impetus for the rapid implementation of vaccination programs.

M a n u s c r i p t 4

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 , numerous viral variants have been characterized. Most genetic variation arises as a result of drift and have no phenotypic effect. However, variants of concern (VOCs) have emerged which carry signature amino acid substitutions in key areas of the immunodominant spike protein, with evidence of altered virus characteristics [1] . For example, VOCs have been associated with increased transmissibility, evasion of immunity from infection and vaccination, and reduced susceptibility to monoclonal antibody therapies [2] [3] [4] . Several VOCs have temporally coincided with spikes of infection rates in countries where they first arose, such as B.1.1.7 (Alpha in the World Health Organization classification) [5] , B.1.351 (Beta) [6] , P.1 (Gamma) [7] , and B.1.617.2 (Delta) [8] .

While robust epidemiologic data have provided evidence for the increased transmissibility of these VOCs [4, 6, 9] , their impact on clinical outcomes such as disease severity and mortality is less clear.

Large population studies have found a significant trend toward increased mortality associated with B.1.1.7 [10, 11] , whereas a cohort of hospitalized patients found no significant difference in disease severity and clinical outcomes compared with non-B.1.1.7 infected patients [12] .

The emergence of B.1.617.2 had a catastrophic impact on infection and mortality rates in India. By May 2021 it had become the dominant strain identified in the UK, and in June-2021 the dominant strain identified worldwide [13] . Early data has showed an association between infections with B.1.617.2 and hospitalization [14] , however, there are limited data on the relationship between B.1.617.2 and clinical outcomes such as disease severity or mortality. National infection and mortality rates can be confounded by factors such as healthcare resource utilization, demographics, and socio-behavioral trends, and detailed cohort studies are required to distinguish the impact of viral versus non-pathogen factors [15] .

A c c e p t e d M a n u s c r i p t 5 Singapore has employed a robust test-trace-isolate strategy in a largely successful effort to limit community transmission of SARS-CoV-2. This includes detailed contact-tracing efforts, rigorous screening of symptomatic and asymptomatic contacts, and quarantine of all positive cases and incoming travelers [16] . This system has been in place since the start of the outbreak in January-2020 with minor adjustments, but without significant change to the overarching strategy. Active case finding provided a high rate of diagnosis, and accumulation of clinical data across the entire spectrum of COVID-19 disease severity [17] .

In this retrospective study of both a national cohort dataset of all confirmed COVID-19 cases and a smaller single-center cohort of hospitalized patients, we compared the outcomes of patients There were no exclusion criteria.

Patients with VOC infection were compared with a cohort of 846 consecutive patients admitted to NCID from 22-January-2020 to 15-April-2020 (henceforth referred to as "wild-type"). Viral shedding dynamics of the three VOCs were compared with wild-type virus using a database of RT-PCR Ct values in 63 patients admitted from January to April-2020 with available serial Ct value data, previously reported in a separate study [18] .

Clinical information was extracted from the medical record using a standardized data-collection form adapted from the International Severe Acute Respiratory and Emerging Infection Consortium M a n u s c r i p t 7 We also obtained anonymized national mandatory case report data submitted to the Ministry of Health (Singapore) from 1-January-2021 to 22-May-2021. The data submitted by all healthcare institutions is implemented and analyzed under the Infectious Diseases Act (Singapore). It included all known patients with COVID-19 infection in the country during this period. Available metadata were age, sex, VOC type, and clinical outcomes (oxygen requirement, intensive care unit [ICU] admission, and death). National-level data on whether patients developed pneumonia were not available.

All patients were admitted to airborne-infection isolation rooms. Risk stratification was conducted at the discretion of managing physicians based on age, comorbidities, radiographic and laboratory findings, and low-risk patients were transferred to a separate designated community isolation facility. High-risk patients with pneumonia (presence of pulmonary opacities on chest radiograph) were treated with intravenous remdesivir for five days, while patients requiring supplemental oxygen were treated with dexamethasone per national guidelines [20] . Patients were de-isolated based on discharge criteria of (a) two negative swabs for SARS-CoV-2 PCR, (b) seroconversion with one negative swab for SARS-CoV-2 PCR, or (c) three weeks from illness onset. Repeat PCR testing was conducted at intervals decided by individual managing physicians.

SARS-CoV-2 PCR was performed with a range of commercially available assays used by the clinical laboratory. Sequencing was performed at a centralized laboratory (NPHL, the national infectious diseases reference laboratory) and Pangolin COVID-19 Lineage Assigner and CoVsurver were used to assign lineage to each sequence [21, 22] .

A c c e p t e d M a n u s c r i p t 8

The primary endpoint for the retrospective NCID cohort study was development of pneumonia as defined by presence of pulmonary opacities on chest radiograph. This was chosen as the primary end-point due to the expected small numbers of patients with severe infection outcomes. For the national cohort, primary outcome was severe COVID-19, defined as a composite of any of the following outcomes: hypoxia requiring supplemental oxygen (both low-flow including nasal prongs or high-flow), ICU admission and/or death. Secondary outcomes were comparison of viral PCR Ct values and duration of viral shedding between VOCs.

Firth's logistic regression was used to examine the association between variant type and development of pneumonia due to the potential for the presence of separation with zero cell frequency for a particular variant. The following covariates known to impact COVID-19 disease severity were selected for inclusion in the multivariable logistic regression model: age group, sex, comorbidities, COVID-19 vaccination history and SARS-CoV-2 lineage. For the national cohort the multivariable logistic regression model included only age group, sex, and lineage due to the lack of other available data.

We fitted a generalized additive mixed model (GAMM) to the serial Ct values with random intercept by patient ID in addition to the fixed factor of day of illness with smoothing terms, separately for cases infected with B.1.1.7, B.1.351 and wild-type. We included random slope of Ct values with respect to day of illness (in addition to random intercept) for cases infected with B.1.617.2. We To compare duration of infectivity, we used Kaplan-Meier curves to describe time from symptom onset to first Ct value >30 and log-rank test for comparison between variants. An event was defined A c c e p t e d M a n u s c r i p t 9 as the first Ct value >30 as a surrogate indicator for end of the infective period, since Ct values above this cut-off have been shown to be associated with lack of positive viral culture [23, 24] . A patient was considered censored if he or she did not have Ct value >30 as of the date of last available Ct value.

Data analysis was done in the R statistical language (version 3.6.1). All statistical tests were twosided, and p-values <0.05 considered statistically significant. In a multivariable logistic regression model, after adjustment for age, sex, comorbidities, and vaccination status, B.1.617.2 was associated with higher odds of pneumonia though this was not statistically significant (aOR 1.88; 95% CI 0.95-3.76) ( 

In this retrospective cohort study comparing three VOCs with wild-type SARS-CoV-2, we found a possible association between B.1.617.2 infection and increased severity of COVID-19. This finding was similar in a broad analysis of Singapore's national-level data and a detailed cohort of patientlevel data with outcomes of severe infection or pneumonia. It is uncertain the extent to which this association reflects an effect of the variant, a chance finding due to relatively small sample sizes, or differences in the groups of individuals that were not accounted for in the multivariable models.

As part of broad-based disease surveillance, all international arrivals to Singapore, close contacts of The association of VOCs with lower Ct values (a surrogate for higher viral loads) and a longer duration of viral shedding has important implications on transmissibility. B.1.1.7 has been shown in multiple studies to have increased respiratory shedding [12, 26, 27] . We demonstrate that this is seen in B.1.617.2 as well. Although patients with B.1.617.2 presented earlier in the illness course in our cohort, the observed higher viral load is sustained across the entire duration of illness up to day 21, which would not have been impacted by timing of presentation or diagnosis. These virologic data provide a mechanism to support the epidemiologic data suggesting greater transmissibility of these VOCs [28] . Infection control policy with regard to duration of isolation of infected patients, and public health control policies to reduce population-level transmission, may have to be relooked given higher viral loads and prolonged shedding, and further study should quantify the duration of infectivity by subjecting interval respiratory specimens to viral culture. Higher viral loads have been associated with COVID-19 morbidity and mortality in some studies, though inconsistently and it is not clear whether this reflects cause or effect [29, 30] . [31] [32] [33] [34] . A separate study of vaccine-breakthrough infections by B.1.617.2 has also shown reduction in clinical severity with faster decline in viral loads in vaccinated individuals [35] . Detailed epidemiologic investigation was beyond the scope of this study, and we could not perform calculations of vaccine effectiveness against VOCs in our cohort. The population vaccination program in Singapore started in January 2021, and coverage increased gradually to 26% at the end of the study period [36] . Further study should evaluate vaccine effectiveness against emerging variants against both transmission and severe disease.

There are several limitations to this study. Firstly, due to the small sample size, there were few patients requiring supplemental oxygen or ICU admission, and fewer deaths. Smaller but statistically significant differences in clinical presentation with VOCs could have been missed due to inadequate power. For example, large population studies in the UK have found a signal toward increased mortality associated with B.1.1.7, which was not observed in a smaller cohort of hospitalized patients [10, 11, 37] . Larger cohort studies comparing different VOCs should be conducted to corroborate our findings. Secondly, as this was a retrospective study, testing was not protocolized and PCR testing was conducted on the basis of assessment by individual managing physicians. Initial respiratory samples were also not processed in a centralized laboratory, and hence estimation of viral load and shedding using Ct value is only a surrogate measure. However, SARS-CoV-2 testing protocol in Singapore is conducted in a standardized manner using only validated PCR assays, and any possible inter-assay variability would have been distributed equally across the entire cohort. Lastly, there are important differences between the control cohort from 2020 and the VOC cohort from 2021, which introduce bias to comparison between these cohorts. However, better management and treatment protocols, and improved testing and contact tracing (with a resultant higher proportion of asymptomatic [17.2% in VOC cohort vs 0.6% in wild-type cohort] and early infections) in the VOC cohort are expected to have biased toward decreased severity compared to retrospective controls. Due to the limited ability to adjust for other unrecognized confounders, these findings, while of concern, should be interpreted with caution. There were also limited virologic and sequencing data available from wild-type infections in 2020, though this would not have impacted the difference in viral loads observed between B.1.617.2 and other two VOCs studied.

In this retrospective study, we found a possible association between infection by the B. 

Informed consent for retrospective data collection was waived as approved by the institutional review board (NHG-DSRB reference number 2020/01122).

This study was funded by grants from the Singapore National Medical Research Council (COVID19RF-001, COVID19RF-008). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. The corresponding authors have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Refers to other non-VOC variants and wild-type. ^Includes those that were unable to be sequenced and not sequenced. 

SARS-CoV-2 variants, spike mutations and immune escape

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Will SARS-CoV-2 variants of concern affect the promise of vaccines?

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Detection of a SARS-CoV-2 variant of concern in South Africa

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

Coronavirus variants are spreading in India -what scientists know so far

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes

Interrupting transmission of COVID-19: lessons from containment efforts in Singapore

Effectiveness of Containment Measures Against COVID-19 in Singapore: Implications for Other National Containment Efforts

Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Viral dynamics and immune correlates of COVID-19 disease severity

Predicting infectious SARS-CoV-2 from diagnostic samples

SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 14

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs

Threat Assessment Brief: Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

SARS-CoV-2 viral load is associated with increased disease severity and mortality

National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study

Live COVID-19 Vaccination Tracker -Singapore

Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 19 

Symptom onset to admission, days (median, IQR)